BioAtla (BCAB)

• Market cap: $7.27M
• 1 day: -6.81%
• 5 days: -0.45%
• 1 month: -22.48%
• 3 months: -53.94%
• 6 months: -86.42%
• Year to date: -83.6%
• 1 year: -83.08%
• 5 years: -99.81%
• 10 years: -99.72%
• Sector: Healthcare
• Industry: Biotechnology

About: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Employees: 41